Oct 10, 2022 4:45pm EDT Rigel Provides Update on Plans for sNDA for wAIHA Program Following FDA Feedback
Sep 06, 2022 8:30am EDT Rigel to Present at the H.C. Wainwright 24th Annual Global Investment Conference
Aug 02, 2022 4:02pm EDT Rigel Reports Second Quarter 2022 Financial Results and Provides Business Update
Aug 02, 2022 4:01pm EDT Rigel Pharmaceuticals and Forma Therapeutics Announce Licensing Agreement for Olutasidenib, a Novel Mutant IDH1 Inhibitor for the Potential Treatment of Relapsed or Refractory Acute Myeloid Leukemia
Jul 26, 2022 8:30am EDT Rigel Announces Conference Call and Webcast to Report Second Quarter 2022 Financial Results and Business Update
Jun 08, 2022 7:00am EDT Rigel Announces Top-line Results from FORWARD Phase 3 Clinical Trial of Fostamatinib in Patients with Warm Autoimmune Hemolytic Anemia
May 03, 2022 4:01pm EDT Rigel Reports First Quarter 2022 Financial Results and Provides Business Update
Apr 26, 2022 8:30am EDT Rigel Announces Conference Call and Webcast to Report First Quarter 2022 Financial Results and Business Update
Mar 08, 2022 8:05am EST Rigel Announces Publication of Data from Phase 2 Clinical Study of Fostamatinib for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia in the American Journal of Hematology
Mar 01, 2022 4:01pm EST Rigel Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
